INVOcell Review Published in Current Opinion in Obstetrics and Gynecology
INVO Bioscience, Inc. (NASDAQ: INVO), a fertility-focused company, announced a new publication on intravaginal culture (IVC) in Current Opinion in Obstetrics and Gynecology. The review by Dr. Amber R. Cooper discusses IVC as a viable alternative to standard IVF, showing similar success rates and increased accessibility for patients. INVOcell®, the company's flagship device, facilitates this procedure, aiming to provide affordable and effective fertility treatments. Currently, three INVO Centers are operational in North America, contributing to the rising adoption of IVC.
- Publication in a reputable journal enhances credibility and awareness of IVC.
- IVC is presented as a successful alternative to traditional IVF, suggesting potential market expansion.
- INVOcell® facilitates a more affordable fertility treatment, aligning with market demand for cost-effective solutions.
- Operational INVO Centers in North America support immediate service delivery and brand visibility.
- None.
SARASOTA, Fla., Oct. 21, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the publication of a review discussing existing literature and current use of intravaginal culture (IVC) as an option for patients seeking fertility therapies. The review, titled "Intravaginal embryo culture: a successful alternative to standard IVF that may improve access to care," by Dr. Amber R. Cooper was published in the Current Opinion in Obstetrics and Gynecology.
Findings included:
- Intravaginal culture (IVC) of embryos is a successful and well-tolerated option for many patients.
- IVC has similar outcomes when compared to standard IVF with or without ICSI.
A copy of the publication is available at:
Current Opinion in Obstetrics and Gynecology is a bimonthly publication offering a unique and wide ranging perspective on the key developments in the field. Each issue features hand-picked review articles from our team of expert editors. With eleven disciplines published across the year – including reproductive endocrinology, gynecologic cancer and fertility– every issue also contains annotated references detailing the merits of the most important papers.
About INVO Bioscience
We are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our primary mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Our flagship product is INVOcell®, a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization ("IVF") and is a significantly more effective treatment than intrauterine insemination ("IUI"). Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell ® and IVC procedure (with three centers in North America now operational), in addition to continuing to distribute and sell our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/invocell-review-published-in-current-opinion-in-obstetrics-and-gynecology-301655709.html
SOURCE INVO Bioscience, Inc.
FAQ
What is the significance of the recent publication by INVO Bioscience on IVC?
How does IVC compare to traditional IVF according to INVO Bioscience's recent findings?
What is the current status of INVO Centers for INVOcell®?
When was the review on IVC published?
What are the key benefits of using INVOcell® for fertility treatments?
